Eli Lilly plans to invest more than $3.5 billion in a new injectable medicine and device manufacturing facility in Pennsylvania.
The Lehigh Valley site will manufacture next-generation weight-loss medicines, including retatrutide, and represents Eli Lilly’s 10th U.S. manufacturing site announced since 2020, according to a Jan. 30 company news release. It is the fourth new domestic manufacturing site the company has announced since February 2025.
Lilly said the project will create approximately 850 permanent roles and about 2,000 construction jobs. Construction is expected to begin in 2026, with the site projected to be operational in 2031.
The facility will be located in Fogelsville, Pa., and was selected from more than 300 site applications based on factors including infrastructure, workforce and proximity to universities.
The Pennsylvania investment follows other recent domestic manufacturing commitments by Eli Lilly, including a $5 billion active pharmaceutical ingredient facility announced in Virginia in September 2025 and a $6 billion API plant announced in Alabama in December 2025, as the company continues to expand its U.S. manufacturing footprint.
